Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Mind Medicine (MindMed) Inc MNMD

Alternate Symbol(s):  N.MMED.WA | N.MMED.WR | N.MMED.WS | N.MMED

Mind Medicine (MindMed) Inc. is a clinical-stage biopharmaceutical company, which is engaged in developing products to treat brain health disorders. It is developing a pipeline of product candidates, with and without acute perceptual effects, targeting neurotransmitter pathways. This specifically includes pharmaceutically optimized product candidates derived from the psychedelic and empathogen drug classes, including MM-120 and MM-402, the Company's product candidates. MM120, is a proprietary, pharmaceutically optimized form of lysergide D-tartrate that it is developing for the treatment of generalized anxiety disorder (GAD). MM-120 is also being studied in a subperceptual repeat administration dosing regimen for the treatment of attention deficit hyperactivity disorder (ADHD). MM-402, also referred to as R(-)-MDMA, is the Company's form of the R-enantiomer of 3,4-methylenedioxymethampheta (MDMA), which the Company is developing for the treatment of autism spectrum disorder (ASD).


NDAQ:MNMD - Post by User

Bullboard Posts
Comment by TedOwenson Dec 25, 2013 4:16pm
485 Views
Post# 22037854

RE:RE:RE:RE:RE:RE:RE:RE:Kiska Files Statement of Claim Against St Andrew Goldfields

RE:RE:RE:RE:RE:RE:RE:RE:Kiska Files Statement of Claim Against St Andrew Goldfields That is exactly the point. Primero's deal with Brigus is really about the upside potential of potential resource returns outside of the known Black Fox corridor...........Grey Fox is looking a whole lot more prospective as a result of the huge deep hole returns at Black Fox........... Modeling diagnosis clearly references an increase in prospective volumetric expansion being in place to the south of Black Fox and trending towards Grey-Fox where a stair casing effect can be seen along the east-west trending Arrow Fault........... The Grey Fox system is a widening corridor whose potential is enhanced considerably by the Ross Syenitic belt influence at the junction of the Arrow and Gibson-Kelore Fault Zones........ There is considerable reason for concern that Primero understands a heck of a lot more about what the Grey Fox has in store towards potentiality and it is clear at this point that either Brigus management understands this or it does not. Brigus should not go through with the Primero deal and this will be more clearly understood when the later drill results are returned from both Brigus and St. Andrew Goldfields.
Bullboard Posts